• Monitor U.S. trade policies relating to intellectual property protection under the WTO/TRIPS agreement health care reform legislation
• Follow developments within the Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies; international vaccine issues; vaccine policy at the Pan American Health Organization; Childhood immunizations Dietary supplement issues Alzheimer's care Pediatric Studies and Trials Drug Safety/Clinical Trials Health care reform legislation FDA Pre-emption Follow-on biologics Drug importation and counterfeiting Drug advertising Comparative effectiveness Physician payment disclosure Chronic care out of pocket costs Vaccine Program H.R. 1427 - Access to Life-Saving Medicine Act H.R. 1548 - The Pathway for Biosimilars Act Legislative and regulatory issues related to hormone replacement therapies International public health issues International vaccine issues H.R. 1/S350 - The American Recovery and Reinvestment Act of 2009 H.R. 579 - The Food and Drug Administration Globalization Act S. 525/H.R. 1298 - The Pharmaceutical Market Access and Drug Safety Act of 2009 S. 301 - Physican Payments Sunshine Act of 2009 H.R. 573 - Authorized Generics S. 501 - Fair Prescription Drug Competition Act S. 369 - Preserve Access to Affordable Generics Act H.R. 1706 - Protecting consumer Access to Generic Drugs Act S.357 - Sunshine in Litigation Act of 2009 H.R. 3200 - American's Affordable Health Choices Act of 2009 S.1679 Affordable Health Choices Act S.1213 - Patient Centered Outcomes Research Act of 2009
• Monitor U.S. trade policies relating to intellectual property protection under the WTO TRIPS agreement Importation of FDA-approved pharmaceuticals
• Taxation of International Operations of U.S. corporations generally; R&D tax credit; repatriation of foreign source income; deferral of U.S. taxation of foreign source income; taxation of employer provided healthcare.
• Vaccines Medicare chronic disease coverageImplementation Issues concerning P.L. 108-173 - the Medicare Prescription Drug, Improvement and Modernization Act of 2003 Medicare coverage of pharmaceuticals, Medicare Part D Chronic care out of pocket costs Medicare Prescription Drug Benefit Medicaid drug rebate Medicare and Medicaid Drug Reimbursement Medicaid Part D Non-Interference S.301/HR 3138 Physician Payments Sunshine Act of 2009 S.547/H.R. 904 - Drug Rebate Equalization Act of 2009 H.R. 1725 - Voluntary State Discount Prescription Drug Plan Act of 2009 S.330/H.R. 684 - Medicare Prescription Drug Savings and Choice Act of 2009 S.266 - Medicare Prescription Drug Gap Reduction Act of 2009 S.1679 Affordable Health Choices Act
• FDA reform proposals; Pseudoephedrine H.R. 1259 DXM Distribution Act Monograph System Reform Proposal Pseudoephedrine Electronic Log Proposal S.1383 Dextromethorphan Abuse Reduction Act of 2009 H.R. 2749 Food Safety Enhancement Act of 2009 S. 510 Food Safety Modernization Act of 2009
• S. 726/H.R. 1427 - Access to Life-Saving Medicine Act, Follow-on Biologics H.R. 1548 - The Pathway for Biosimilars ActBiosimilars Drug Safety Prescription Drug Importation Import Safety Compounding H.R. 759 - Food and Drug Administration Globaliation Act of 2009 S. 510 - FDA Food Safety Modernization Act

Duration: January 1, 2008 to September 30, 2009

General Issues: Copyright/Patent/Trademark, Health Issues, Trade (Domestic & Foreign), Taxation/Internal Revenue Code, Medicare/Medicaid, Consumer Issues/Safety/Protection, Pharmacy, Budget/Appropriations

Spending: about $5,761,836 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2008: House of Representatives, U.S. Senate, Natl Security Council (NSC), U.S. Trade Representative (USTR), State - Dept of (DOS), Health & Human Services - Dept of (HHS), Justice - Dept of (DOJ), Executive Office of the President (EOP), Natl Security Agency (NSA), Treasury - Dept of, Food & Drug Administration (FDA), White House Office, State - Dept of (DOS),, Centers For Medicare and Medicaid Services (CMS),, Office of the Vice President of the United States, Centers For Medicare and Medicaid Services (CMS)